Matt Feldman, MD

Articles by Matt Feldman, MD

Key Takeaways on the Optimal Management of Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

Closing out their discussion on the management of atopic dermatitis, expert panelists share clinical pearls and key takeaways from their discussion.

Educating Patients on Atopic Dermatitis and Inflammation

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

Shared insight on the best ways to educate patients on their atopic dermatitis and explain the nuances of available therapies.

Unmet Needs in the Management of Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

A broad look at the ongoing challenges and unmet needs in the field of atopic dermatitis management.

Challenges in Treating AD: Heterogeneity of Disease

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

Marc Serota, MD, elucidates the heterogeneity of atopic dermatitis and explains how this can contribute to challenges in treating patients.

Emerging Systemic Therapy for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

Expert panelists share excitement for novel therapies in the pipeline for the management of atopic dermatitis.

Optimal Sequencing of Therapy for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

Taking into account all available topical and systemic therapies, Marc Serota, MD, provides his optimal sequencing strategy for patients with atopic dermatitis.

Atopic Dermatitis: Breaking Down the AE Profile of JAK Inhibitors

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

Drs. Lio, Feldman and Jain reflect on the adverse event profile of JAK inhibitor therapy in atopic dermatitis and consider when these agents are appropriate for use.

JAK Inhibitors for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 21st 2022

An overview of the three JAK inhibitor therapies available for the management of atopic dermatitis.

Interleukin Pathway Inhibitors for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

Expert perspectives on the interleukin pathway inhibitors, dupilumab and tralokinumab, and their role in managing atopic dermatitis.

Managing Atopic Dermatitis During the COVID-19 Pandemic

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

A brief discussion on how the coronavirus 2019 pandemic has impacted the management of patients with atopic dermatitis.

Atopic Dermatitis: Treating Mild-to-Moderate vs Moderate-to-Severe Disease

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

Considerations for managing mild-to-moderate versus moderate-to-severe atopic dermatitis and which therapies are appropriate in each setting.

Overview of Systemic Therapy Options for Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

Shared insight on the systemic treatment armamentarium for atopic dermatitis and how it has evolved in recent years.

Selecting Therapy for Atopic Dermatitis: Topical Treatment Options

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

Moving on to discuss treatment options for patients with atopic dermatitis, experts reflect on optimal use of topical agents in this setting.

Role of Guidelines and Shared-Decision Making in Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 18th 2022

A panel of experts discuss role of guidelines and importance of shared-decision making in managing patients with atopic dermatitis.

Assessing Impact of AD on Quality of Life

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 11th 2022

Expert perspectives on assessing quality of life when discussing atopic dermatitis and inflammatory disease with patients.

An Overview of Type 2 Inflammation and Atopic Dermatitis

ByPeter Lio, MD ,Neal Jain, MD,Marc Serota, MD,Matt Feldman, MD

March 11th 2022

Shared insight on the nature of inflammation in conjunction with atopic dermatitis with special considerations for possible contributors and severity of disease.